Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-amino-3-(5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl)propionic acid
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
A synthetic small molecule and experimental compound, 2-amino-3-(5-tert-butyl‑3‑(phosphonomethoxy)‑4‑isoxazolyl)propionic acid (commonly known as ATPO), is a structural analog of amino acids in the isoxazole class. It acts primarily as a competitive antagonist at AMPA-type ionotropic glutamate receptors (GluR1–GluR4), with weak partial agonist activity at certain kainate receptor subtypes such as GluR5 and GluR5/KA2. ATPO inhibits AMPA receptor-mediated currents in recombinant systems with micromolar affinity, showing selectivity for AMPA over NMDA or most kainate receptors. The compound has been used experimentally to probe glutamatergic neurotransmission but has not advanced to clinical development or approval[1][5][9].
- Other names
- (S)-2-amino-3-(5-tert-butyl-3-(phosphonomethoxy)isoxazol-4-yl)propanoic acid(2S)-2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-1,2-oxazol-4-yl]propanoic acid252930–37–3
02
Targets
GRIA1 (AMPA receptor subunit GluA1)GRIA2 (AMPA receptor subunit GluA2)GRIA3 (AMPA receptor subunit GluA3)GRIA4 (AMPA receptor subunit GluA4)GRIK1 (Glutamate ionotropic receptor kainate type subunit 1)
Beyond the preview
Go deeper on 2-amino-3-(5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl)propionic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2-amino-3-(5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl)propionic acid.